REGULATORY

Japan Restarts Deliberations on Routine Mumps Vaccination, Eyes FY2027 Rollout

June 22, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A Japanese health ministry panel on June 19 resumed discussions on including the mumps vaccination in the country’s national immunization program (NIP), reviewing evidence on efficacy, safety, and cost-effectiveness, including data on Daiichi Sankyo’s newly approved measles-mumps-rubella (MMR) vaccine Mimrit.…

To read the full story

Daiichi Sankyo Wins Japan Approval for MMR Vaccine Mimrit
May 12, 2026
Impasse Continues over Mumps Vaccine Inclusion in Public Immunization Programs
August 20, 2018

REGULATORY

Japan Approves Wegovy MASH Use, AstraZeneca’s Etcamah, Others
June 22, 2026
Japan on Alert over US MFN Drug Pricing Policy: Health Minister
June 22, 2026
Japan Restarts Deliberations on Routine Mumps Vaccination, Eyes FY2027 Rollout
June 22, 2026
LDP Group Calls for Pediatric Cancer Drug Development Platform
June 22, 2026
LDP Group Seeks Better Access to Advanced Eczema Care
June 22, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…